The tuberous sclerosis complex (TSC) family of tumor suppressors, TSC1 and TSC2, function together in an evolutionarily conserved protein complex that is a point of convergence for major cell signaling pathways that regulate mTOR complex 1 (mTORC1). Mutation or aberrant inhibition of the TSC complex is common in various human tumor syndromes and cancers. The discovery of novel therapeutic strategies to selectively target cells with functional loss of this complex is therefore of clinical relevance to patients with nonmalignant TSC and those with sporadic cancers. We developed a CRISPR-based method to generate homogeneous mutant Drosophila cell lines. By combining TSC1 or TSC2 mutant cell lines with RNAi screens against all kinases and phosphatases, we identified synthetic interactions with TSC1 and TSC2. Individual knockdown of three candidate genes (mRNA-cap, Pitslre, and CycT; orthologs of RNGTT, CDK11, and CCNT1 in humans) reduced the population growth rate of Drosophila cells lacking either TSC1 or TSC2 but not that of wild-type cells. Moreover, individual knockdown of these three genes had similar growth-inhibiting effects in mammalian TSC2-deficient cell lines, including human tumor-derived cells, illustrating the power of this cross-species screening strategy to identify potential drug targets.
INTRODUCTION
The tuberous sclerosis complex (TSC) protein complex is a point of convergence of multiple upstream signaling pathways that is vital for the control of growth and proliferation in response to extracellular signals. Genetic disruption of the TSC protein complex, through mutations in TSC1 or TSC2, gives rise to the TSC and lymphangioleiomyomatosis (LAM) diseases, which are systemic disorders associated with the development of widespread neoplastic lesions (1) . Current therapeutic strategies targeting the TSC complex and the surrounding network include the target of rapamycin (TOR) inhibitor rapamycin and its derivatives. However, such treatments are limited to cytostatic effects, and tumors rapidly regrow after cessation of treatment (2) (3) (4) , underscoring the need to identify new therapeutic targets for the treatment of TSC. A common limitation of chemotherapeutic agents is toxicity to healthy tissues, limiting the dose and duration of treatment and thereby restricting their efficacy. Therefore, we sought to identify potential drug targets with synthetic effects in combination with TSC complex components, in which knockdown of the target gene alone has little effect on normal cells but is toxic to TSC-deficient cells.
RNA interference (RNAi) screens in mammalian cells have been extensively used to identify novel drug targets for various tumor types, and results from these studies have led to the identification of a number of candidates. However, many candidates identified from such screens have suffered from reproducibility issues, and as such, few functional therapeutic targets have emerged (5) . One way to address this issue is to perform cross-species screens because candidates with conserved effects between organisms are more likely to be functional therapeutic targets in follow-up studies (6) . Because the TSC signaling network is conserved between Drosophila and mammals and robust methods for Drosophila cell-based screens have been established (6) , we decided to perform combinatorial screens in Drosophila cells to identify synthetic interactions with TSC1 and TSC2 (also known as Gigas) and evaluate whether the identified candidates had conserved synthetic effects in mammals.
As demonstrated in yeast studies, combinatorial screening is an effective way to identify synthetic interactions (7, 8) . However, when multiple RNAi reagents are used in combination, the consequences of off-target effects and variable knockdown efficiencies are compounded, leading to high falsepositive and false-negative rates (9, 10) . Deconvolving biologically meaningful candidates from such screens requires extensive secondary screening and validation, making this approach time-consuming and expensive.
Here, we first describe a method for the generation of isogenic mutant Drosophila cell lines, which we then used for synthetic screens in Drosophila cells that combined CRISPR-generated cell lines deficient in TSC1 or TSC2 with RNAi screening methods. By combining these two technologies and screening in two independent TSC mutant backgrounds, we identified three robust candidate drug targets without needing to perform secondary screening. We demonstrated that all three of these candidates have conserved synthetic interactions with TSC2 in mouse embryonic fibroblasts (MEFs) and human tumor-derived cell lines, illustrating the power of this approach to identify potential candidates for therapeutic targeting.
is unclear whether design rules from mammalian systems are transferable to Drosophila cells (20) (21) (22) (23) . We therefore decided to assess the specificity of CRISPR in Drosophila cell culture. We first generated a vector encoding both Cas9 and sgRNA (Supplementary file 1) and then used this to express 75 variants of an sgRNA in S2R+ cells with different mismatches to a single target sequence present in a luciferase-based reporter (Supplementary file 2) or in the genome. The extent and position of mismatch required to prevent mutation was assessed by measuring changes in luciferase expression from the reporter construct (Fig. 1A) or using high-resolution melt assays (HRMAs) on endogenous sequences ( fig. S1 ). Both approaches produced similar results that are consistent with previous observations (13, 24) . For example, in previous reports from mammalian systems (21) , mismatches at the 5′ end of the sgRNA sequences were better tolerated than those at the 3′ end. However, in some cases, a single mismatch was sufficient to prevent detectable mutation. In addition, we found that three mismatches were sufficient to prevent detectable mutations except when all mismatches were at the 5′ end of the sgRNA, consistent with a previous report investigating the specificity of CRISPR in vivo in Drosophila (25) . We therefore used 3 base pairs (bp) of mismatch as a cutoff to annotate predicted off-targets for all possible sgRNAs in the Drosophila genome and included these data in an updated version of our previously reported sgRNA design tool (www.flyrnai.org/ crispr2) ( fig. S2) (16) . Note that to be included in this tool, sgRNAs must have a unique 3′ seed sequence. As such, no annotated sgRNA can have offtargets with mismatches clustered at the 5′ end. Using these updated offtarget predictions, we estimate that 97% of genes in the Drosophila genome can be targeted with specific sgRNAs, making this an ideal system for the generation of knockout cell lines.
Because the rate of mutations varies widely between different sgRNAs (26-28), we tested whether efficiency could be predicted on the basis of the sgRNA sequence. We generated 75 additional sgRNAs each targeting luciferase-based reporter constructs with no mismatches and tested mutation efficiency for each (table S1). Using this panel of sgRNAs and associated efficiencies, we first considered whether GC content correlated with mutation rate as has been suggested in several previous reports (25, 27, 29, 30) . In contrast with the results of Ren et al. (25) suggesting that greater than 50% GC content in the six PAM (protospacer-adjacent motif)-proximal nucleotides is associated with high efficiency, we found no such correlation for any part of the sgRNA sequence ( fig. S3 , A to C). However, our observations are consistent with a mammalian study suggesting that both high and low GC content at the 3′ end are associated with low efficiency [ fig. S3B and (27)]. Next, we tested whether a more general sequence-based approach could improve efficiency prediction. We analyzed the nucleotide content of all 75 sgRNAs considering each position separately and generated a probability matrix linking nucleotide content with mutation rate (Fig. 1B) , which was used to predict efficiency scores based on sgRNA sequence. To test the performance of this approach, we generated scores for sgRNAs used in three previous Drosophila publications and found a strong correlation with reported efficiencies for two of them (Fig. 1C) . Note that sgRNAs unlikely to produce a mutant phenotype (targeting close to the 3′ end of genes) or with apparent viability effects (few emerging adults) were not included in this analysis. However, very little correlation was detected for a third data set ( fig. S3D ). In addition, the criteria that we identified for high sgRNA efficiency differ from those of two studies performed in mammalian systems (26, 27) , and these two studies also differ from the GC requirements identified previously in Drosophila (25) , suggesting that in some cases, efficiency criteria may depend on factors other than simply sgRNA sequence. Finally, we generated predicted scores for all sgRNA target sites in the Drosophila genome on the basis of our findings and annotated these in our online design tool (www.flyrnai.org/ crispr2) ( fig. S2 ). With this updated tool, sgRNAs can be quickly designed for various applications.
Generation of stable mutant cell lines
The CRISPR system works efficiently in Drosophila cell culture (11, 12) . However, it has not yet been possible to generate cell lines in which all cells are null mutants for the target gene, because previous studies have shown that mutant populations quickly revert back to wild type. To solve this issue, we first generated optimized sgRNAs to maximize their efficiencies while avoiding off-target effects ( Fig. 1 and fig. S2 ). In addition, we implemented a method to predict the frameshift and in-frame mutation rates for each sgRNA target site (31) and annotated each of these mutation rates in our Fig. 2A) . Varying the fetal bovine serum (FBS) concentration had no additional effect. One difficulty associated with the isolation of mutant cells from Drosophila S2R+ cells is that they are aneuploid, containing roughly four copies of any given genomic locus (35) . Thus, the chances of identifying cells in which all alleles carry frameshift mutations are considerably lower than for diploid cells. To assess the ability of CRISPR to produce homozygous mutations in these cells, we targeted the yellow gene and tested 30 individual cells for the presence of mutations using high-resolution melt (HRM) assays. Twenty-one (70%) carried mutations at the target locus (Fig. 2B) . The eight samples with the strongest signal in the HRM assays were analyzed by sequencing. No wild-type sequences were detected for any of these samples, and seven of eight contained a single mutation in all derived sequences ( fig. S4 ). The identification of homozygous mutations in seven of eight cells tested is consistent with previous reports of high rates of gene conversion after genome editing (36) (37) (38) ; however, it is also possible that homozygous mutations are generated as a result of chromosome loss. Therefore, the HRM assay is an effective method to identify fully mutant clones.
Next, to test the efficacy of our sgRNA design tool and the combined CRISPR and single-cell cloning approach ( fig. S5A ), we targeted a gene for which loss of protein function could easily be assayed: STAT92E, which encodes a STAT (signal transducer and activator of transcription) transcription factor that is activated by JAK (Janus kinase) ( fig. S5B ). Fifteen clones were analyzed, of which 13 carried mutations on all alleles. Further testing showed that the expected phenotype was produced from these knockouts, with the STAT92E line unable to respond to JAK/STAT pathway stimulation induced by upd ligand overexpression (Fig. 2C ). In addition, the effect of the STAT92E mutation was considerably stronger than that produced by targeting STAT92E with double-stranded RNA (dsRNA), which reduced the response to JAK/STAT pathway stimulation but did not prevent it. These results demonstrate that our approach provides an efficient CRISPR-based method for the production of stable, homogeneous mutant Drosophila cell lines.
Synthetic screens using TSC1 and TSC2 mutant lines
We generated cell lines carrying frameshift mutations in the TSC1 and TSC2 genes using the approach described above ( fig. S6 ). To characterize the lines, we tested whether they showed phenotypes similar to those previously reported in vivo or in mammalian cell lines (39-43) because antibodies against Drosophila TSC1 or TSC2 are not available. Three phenotypes were considered: cell size, responsiveness to growth factor deprivation, and phosphorylation of the downstream TOR target S6 kinase (S6K). TSC1 and TSC2 cell lines had all three phenotypes: an increased cell diameter (Fig. 3 , A to D), an inability to modify population growth in the absence of growth factors (Fig. 3E) , and increased phosphorylation of S6K (when normalized to a-tubulin; Fig. 3 , F and G). To further characterize the mutant cell lines, we performed phosphoproteomic analysis. One hundred twenty-eight phosphosites showed a more than 1.5-fold increase or decrease in both mutant lines compared to wild-type cells (table S2) . Gene ontology (GO) analysis demonstrated that 20 of the top 30 most significantly enriched categories were consistent with known functions of the TSC network ( Fig. 3H and table S3), including insulin signaling, response to nutrients, and the growth of cells and tissues. Together, these results suggest that the cell lines accurately represent TSC mutant models.
Next, to take advantage of the homogeneous TSC1 and TSC2 mutant cell lines, we performed a combinatorial RNAi screen of all Drosophila kinases (376) and phosphatases (159). We measured population viability using a total adenosine triphosphate (ATP) readout to capture changes in cell growth, proliferation, and cell death (referred to as "population growth" from here on). Any samples with significant effects on the population growth of wild-type cells were discarded to identify TSC-specific hits. Twenty of the remaining knockdowns had significant effects on TSC1 mutant cells, and 49 hits significantly affected TSC2 mutant cells (Fig. 4A and  table S4 ). Because TSC1 and TSC2 act as part of a protein complex and mutations in either gene give rise to the TSC disease, we decided to consider for further studies genes that were identified in both the TSC1 and TSC2 screens. This approach filtered out the noise associated with either individual screen and identified genes with the most robust synthetic interactions with the TSC complex. The knockdown of three genes (mRNA-cap, Pitslre, and CycT) showed robust and specific effects on TSC1-and TSC2-deficient cells (Fig. 4A, purple crosses) . The first candidate, mRNA-cap, is the 5′ triphosphatase and guanylyltransferase that catalyzes the first two steps required for the formation of a 5′ 7-methylguanylate mRNA cap, which is necessary for the initiation of cap-dependent translation (44) . Because activation of mammalian TOR (mTOR) promotes cap-dependent translation initiation through multiple downstream targets (45, 46) , our findings suggest that TSC mutant cells depended on mRNA capping, an event that precedes the steps in translation regulated by mTOR. Our phosphoproteomic analysis identified phophosites on distinct components of the translation initiation machinery, such as Thor, eIF4G, eIF3-S10, and eIF2B, being either increased or decreased in either TSC1, TSC2, or both mutant cell lines compared to control. In addition, phosphorylation changes were detected in both cell lines for two other proteins that directly interact with core components of the translation initiation complex (Ens and Map205, table S2) (47, 48) .
Given the link between TSC signaling and translation initiation, we tested whether another translation initiation component showed a similar synthetic relationship with the TSC mutant cell lines. We knocked down eIF3-S4 in wild-type and TSC1 or TSC2 mutant cells using the same assays as for the kinase and phosphatase screen. Both TSC1 and TSC2 mutant cells had a synthetic decrease in population growth (Fig. 4A, purple circle) , suggesting that the control of cap-dependent translation initiation may be a promising therapeutic target for TSC-dependent and/or mTOR complex 1 (mTORC1) hyperactive disease.
The second candidate, CycT, is a kinase implicated in the regulation of transcriptional elongation (49, 50) . mRNA-cap is recruited to the RNA polymerase II (Pol II) C-terminal domain phosphorylated at Ser 5 to form the 5′ mRNA cap, and CycT promotes RNA Pol II phosphorylation at this site. Thus, the function of CycT may be related to that of mRNA-cap. Finally, the third candidate, Pitslre, is a cyclin-dependent kinase that has been implicated in the regulation of autophagy (51) . Disruption of the TSC complex leads to reduced autophagy, which has been exploited as a potential therapeutic strategy by combining autophagy inhibitors such as chloroquine with mTOR inhibitors (52) .
To determine whether the identified interactions extended to CG6182 (TBC1D7 in mammals), a third component of the TSC complex (53), we tested whether combinatorial knockdown of mRNA-cap, CycT, or Pitslre with CG6182 knockdown produced greater reduction in population growth than either knockdown alone. In all three cases, the combination of dsRNAs targeting the candidate gene and CG6182 produced a synthetic reduction in population growth (Fig. 4B) .
Conservation of synthetic interactions in mammalian cells
Because all three candidates from the Drosophila screens have orthologs in mammals (table S5) , we tested whether the synthetic interactions of mRNAcap, Pitslre, and CycTwith TSC1 and TSC2 were conserved. We used small interfering RNAs (siRNAs) targeting the orthologs of each of the three genes in TSC2-deficient MEFs compared to littermate-derived wild-type MEFs. Both RNGTT (mRNA-cap in Drosophila) and CCNT1 (CycT in Drosophila) knockdowns caused reduced population growth in TSC2 −/− cells compared to wild type, although no synthetic effect was detected with CDK11 (Pitslre in Drosophila) because CDK11 knockdown reduced mTORC1 activity in both wild-type and TSC2 −/− MEFs (Fig. 4C and figs.  S7, A to F, and S8 ). We noted, however, that similar synthetic interactions were not detected when any of the three candidates were knocked down in combination with TSC1, TSC2, or TBC1D7 using combinatorial siRNA treatments ( fig. S9) . These results suggest that although the target proteins were efficiently reduced ( fig. S8 ), either residual protein was sufficient to restore some function or long-term effects of loss of function of the TSC complex were required. In the latter case, although TSC proteins were depleted, the effect might not be detectable because the cells might still have enough of the components normally regulated by TSC. Further, to assess the relevance of these potential drug targets to human tumor cells, we used siRNA to knock down the three hits in a TSC2-deficient human renal angiomyolipoma (AML) cell line derived from a patient with LAM (54). For isogenic comparison, the candidate genes were knocked down using siRNA in the same cell line stably reconstituted with wild-type TSC2. To assess the effectiveness of the TSC2 addback, we measured S6K phosphorylation and cell size with and without TSC2 reconstitution. As expected, TSC2 addback reduced mTORC1 activity and cell size ( fig. S10 ). siRNAs targeting each of the three candidate genes significantly reduced the population growth of TSC2 null cells as assessed by using total ATP as a readout (Fig. 4D and fig. S7 , G to I). In addition, synthetic effects were seen on cell numbers for all three genes (Fig. 4E) . In contrast, two negative control genes that did not score in the Drosophila screen [Src42A (FRK in mammals) and for (PRKG1 in mammals)] showed no synthetic effects (fig. S7, J and K), indicating that the three gene products we have identified could be promising drug targets for TSC and LAM.
DISCUSSION
We have developed a synthetic screening method that combines the CRISPR genome-editing system with well-established RNAi methodologies. Previous combinatorial screens in Drosophila cells have been performed by treating cells with multiple RNAi reagents simultaneously (9, 10) . However, whereas this approach has been used successfully, limitations of RNAi including incomplete transfection, partial knockdown, and off-target effects are compounded, leading to high false-negative and false-positive rates. A laborious and time-consuming secondary screening is therefore required to identify the robust hits from these screens.
The screening strategy we have developed offers several advantages compared to combinatorial RNAi treatment. First, by combining CRISPRgenerated mutant cell lines with single RNAi reagents, we avoid much of the noise associated with dual RNAi-based screening approaches. The use of homogeneous populations of null mutant cells avoids the issues of incomplete transfection and incomplete knockdown. In addition, once generated, in-depth characterization of the mutant cell lines can be performed to establish whether off-target mutations are present. In the case of our screen, this reduction in noise as well as the comparison between two independent mutant cell lines completely avoided the need for secondary screening.
Second, in some cases, mutant cell lines may represent a considerable improvement in the quality of disease models over RNAi-mediated knockdowns. For example, diseases such as TSC are caused by loss-of-function mutations rather than by partial transient reduction in protein abundance. The establishment of a mutant cell line enables cellular adaptation to the induced mutation, likely generating a more representative cellular environment. This is illustrated by the lack of synthetic effects detected using siRNAmediated combinatorial knockdowns in MEFs (fig. S9 ). One implication is that future screens performed in such adapted backgrounds may lead to hits with more reproducible effects in a therapeutic setting.
Third, previous screening strategies have required laborious secondary screening and validation of hits to identify those that are robust. Here, we have simultaneously screened two mutant backgrounds (TSC1 and TSC2). Because both of these proteins act as part of the TSC complex, similar effects are expected from the two knockouts. Therefore, by considering the overlap between these data sets, we were able to quickly identify the most robust candidates. The advantage of this approach is reflected in the fact that the identified synthetic candidates were validated in both mammalian cell types, resulting in a very rapid translation from screening in a model organism to identification of clinically relevant potential drug targets. Finally, by considering conservation between Drosophila and humans, we increase the likelihood of the identified effects being reproducible, an issue that has been a major limitation in previous studies (5) .
Current treatments for TSC-related diseases include rapamycin and its derivatives, which function by blocking mTOR activity downstream of the TSC complex. A problem associated with this approach is that the molecular vulnerabilities caused by mutations in the TSC complex are reversed, thereby reducing the opportunities available to kill affected cells (55) . The targets we have identified here offer the potential to bypass this issue. Indeed, none of the target genes affected the phosphorylation of S6K in AML cells when knocked down, and two (CCNT1 and RNGTT) had no effect on the phosphorylation of S6K in TSC2-deficient MEFs ( fig. S8 ), suggesting that some molecular vulnerabilities caused by mTOR activation may persist after inhibition of these potential drug targets. For example, inhibition of mRNA-cap would not be expected to have direct effects on autophagy and, therefore, may maintain the energy stress associated with TSC mutations. However, further work will be required to determine whether inhibition of these factors is more efficacious than mTOR inhibition.
Finally, whereas we have used mutant cell lines to develop an improved synthetic screening method, there are many other possible applications of stable homogeneous mutant lines, for example, in modeling of diseases caused by single null mutations or epistasis experiments where residual expression of the target gene can complicate interpretation of results. We therefore expect this method to be widely applicable to many different areas of research.
In conclusion, by combining established RNAi screening methods in Drosophila cells with CRISPR genome-editing technology, we have developed a powerful new approach to synthetic screening. The robustness of this method is demonstrated by the conservation of the identified synthetic interactions in mouse and human systems, suggesting that it will be a generally applicable approach to investigate various biological and disease-relevant questions.
MATERIALS AND METHODS

Generation of CRISPR expression vector
A Drosophila codon-optimized Cas9 with a 3xFlag tag and nuclear localization signal elements at both 5′ and 3′ was synthesized by GenScript, and the Drosophila U6 and act5c promoters were polymerase chain reaction (PCR)-amplified from Drosophila genomic DNA (table S6) . These were used to replace the human codon-optimized Cas9 and human U6 and CGh promoters, respectively, of the pX330 (13) plasmid to yield the pl018 plasmid (Supplementary file 1) . sgRNA homology sequences were cloned into pl018 using pairs of DNA oligonucleotides, which were annealed and ligated into Bbs I sites according to a previously described protocol (table S6) (13) .
Luciferase-based mutation reporter assays
The luciferase reporter vector was constructed by PCR amplifying the metallothionein promoter from pMK33 (56) and luciferase gene from pGL3 (table S6) (57) and combining these with annealed oligos containing an sgRNA target site (tables S1 and S6) and a custom-made cloning vector using Golden Gate assembly. Luciferase assays were performed by transfecting S2R+ cells with the relevant pl018 plasmid, luciferase reporter, and pRL-TK (Promega) (to allow normalization of transfection efficiencies between samples) in 96-well plates using Effectene transfection reagent (Qiagen) according to the manufacturer's recommendations. Twenty-four hours after transfection, CuSO 4 was added to the cell medium at a final concentration of 140 mM, and cells were incubated for a further 16 hours. Firefly and Renilla luciferase readings were taken using the Dual-Glo Luciferase Assay System (Promega) and a SpectraMax Paradigm Multi-Mode Microplate Detection Platform (Molecular Devices) according to the manufacturers' instructions.
Online tools
An improved version of CRISPR design tool was implemented reusing some of the modules developed previously (16) . Besides allowing users to choose different off-target thresholds, this version also displays precalculated efficiency score and restriction enzyme annotation. The efficiency score was calculated on the basis of a probability matrix computed using the in vitro cell line data described in Fig. 1A . It reflects a cumulative P value for high efficiency of each nucleotide from position 1 to 20, with higher values representing higher efficiency. A user interface allowing efficiency score calculation for user-provided sequences was also developed as part of the improved tool, which dynamically calculates predicted efficiency scores for each input sequence from position 1 to 20 or over a user-defined region ( fig. S2) .
HRMAnalyzer was written as a series of Matlab programs running under the control of CGI front-end implemented in Perl and JavaScript. The Matlab programs are compiled as stand-alone executable programs and called from within the Perl CGI back-end script. Both tools are hosted on a shared server provided by the Research Information Technology Group (RITG) at Harvard Medical School.
Transfections
Cells were transfected using Effectene transfection reagent (Qiagen) according to the manufacturer's instructions. For generation of mutant cell lines, we used 360 ng of pl018 plasmid and 40 ng of actin-green fluorescent protein (GFP) plasmid as a marker of transfected cells. Transfections were performed in six-well plates and, unless stated otherwise, were incubated for 4 days at 25°C before further processing.
Production of conditioned media
S2R+ cells were incubated with fresh Schneider's medium supplemented with 10% FBS for 16 hours while in log-phase growth. The medium was then filtered to remove the cells and diluted 50% with fresh medium supplemented with FBS to obtain the required final FBS concentration.
Single-cell cloning
Cloning of single cells was performed using fluorescence-activated cell sorting of GFP-marked cells. Untransfected cells were used to determine background fluorescence amounts before selecting the top 10% of GFPexpressing cells for isolation. Individual cells were sorted into 96-well plates containing culture medium. After 2 or 3 weeks of culture, single-cell clones were identified visually and isolated into larger cultures.
HRM assays
PCR fragments were prepared from genomic DNA as described for sequencing analysis. Reaction products were then diluted 1:10,000 before an additional round of PCR amplification using Precision Melt Supermix (Bio-Rad) and nested primers to generate a product <120 bp in length (95°C 3 min; 50 rounds of 95°C 30 s, 60°C 18 s, plate read; 95°C 30 s; 25°C 30 s; 10°C 30 s; 55°C 31 s; ramp from 55°to 95°C and plate read every 0.1°C). Data were analyzed using HRMAnalyzer, available at www.flyrnai.org/HRMA. See table S6 for primer sequences.
Sequence verification of clones
Genomic DNA was prepared from cultured cells by resuspension in 100 ml of lysis buffer [10 mM tris-HCl (pH 8.2), 1 mM EDTA, 25 mM NaCl, and proteinase K (200 mg/ml)] and incubation in a thermocycler for 1 hour at 50°C followed by denaturation at 98°C for 10 min. Target sequences were cloned by PCR using Phusion high-fidelity DNA polymerase (New England Biolabs) according to the manufacturer's recommendations and supplemented with an additional 2.5 mM MgCl 2 (35 cycles: 96°C, 30s; 50°C, 30s; 72°C, 30s). PCR products were gel-purified, cloned into the pCRBlunt II-TOPO vector (Invitrogen), and transformed into Top10 chemically competent cells (Invitrogen). After transformation, single colonies were isolated for sequencing. To assess homozygosity of single-cell samples, a minimum of five colonies were sequenced per sample. For identification of mutant cell lines, a minimum of 20 colonies were analyzed.
Analysis of STAT92E activity
S2R+ and STAT92E cell lines were transfected using Effectene transfection reagent (Qiagen) according to the manufacturer's instructions to introduce upd complementary DNA cloned into pMK33 expression vector, Renilla expression vector (pRL-TK, Promega), and 10X-STAT-luc (58) into experimental samples or pMK33, pRL-TK, and 10X-STAT-luc into control samples. RNAi samples included an additional 50 ng of dsRNA (DRSC ID: DRSC16870 or DRSC37655) from the dsRNA template collection at the Drosophila RNAi Screening Center (DRSC) (www.flyrnai.org). Cells were transfected for 24 hours before the addition of CuSO 4 at a final concentration of 140 mM and incubation for a further 16 hours. Firefly and Renilla luciferase measurements were performed using a SpectraMax Paradigm Multi-Mode Microplate Detection Platform (Molecular Devices).
Cell size assays S2R+, TSC1, and TSC2 mutant cell lines were analyzed using a BD Biosciences LSR Fortessa X-20 cell analyzer to measure forward scatter for each cell as a proxy for cell diameter.
Cell line growth assays
Five thousand cells from each line were seeded into 384-well plates containing 50 ml of culture medium and incubated at 25°C for 5 days. CellTiter-Glo reagent (27 ml; Promega) was added to each well before reading luminescence using a SpectraMax Paradigm Multi-Mode Microplate Detection Platform (Molecular Devices).
Quantitative phosphoproteomics
Phosphoproteomic analysis was performed as described previously (59) . Briefly, S2R+, TSC1, or TSC2 mutant cells were serum-starved for 16 hours before lysis in 8 M urea. Samples were then digested with trypsin, and peptides were chemically labeled with TMT Isobaric Mass Tags (Thermo Scientific), separated into 12 fractions by strong cation exchange chromatography, purified with TiO 2 microspheres, and analyzed by liquid chromatographytandem mass spectrometry on an Orbitrap Velos Pro mass spectrometer (Thermo Scientific). Peptides were identified by Sequest and filtered to a 1% peptide false discovery rate (FDR). Proteins were filtered to achieve a 2% final protein FDR (final peptide FDR near 0.15%). TMT reporter ion intensities for individual phosphopeptides were normalized to the summed reporter ion intensity for each TMT label. The localizations of phosphosites were assigned using the Ascore algorithm.
Synthetic screening
S2R+, TSC1, and TSC2 mutant cell lines were each screened in triplicate using the "kinases and phosphatases" sublibrary provided by the DRSC (www.flyrnai.org). Screening was performed following standard procedures as described by the DRSC (www.flyrnai.org/DRSC-PRR.html). Briefly, for each 384-well plate, 5000 cells in 10 ml of FBS-free medium were seeded into each well, already containing 5 ml of dsRNA at a concentration of 50 ng/ml. Samples were incubated at room temperature for 45 min before adding 35 ml of 14% FBS medium (bringing the final FBS concentration to 10%). The plates were incubated at 25°C for 5 days before assaying ATP concentrations using CellTiter-Glo assays (Promega) and a SpectraMax Paradigm Multi-Mode Microplate Detection Platform (Molecular Devices). The CellTiter-Glo Luminescent Cell Viability Assay determines the number of viable cells in culture on the basis of quantitation of the ATP present, thus measuring changes in cell growth, proliferation, and/or cell death (population growth).
CellTiter-Glo data were analyzed by normalizing the data to the median value of each column (to correct for pipetting errors) and calculating the z-scores for each trial individually. Z-scores greater than 1.5 or less than −1.5 in at least two of three trials were considered to affect population growth significantly. Synthetic hits were identified as dsRNAs that significantly affect the population growth of TSC1 or TSC2 mutant cell lines but not S2R+.
Validation of synthetic interactions in mammalian cells
TSC2
+/+ ;TP53 −/− and TSC2 −/− ;TP53 −/− MEFs (60) and TSC2-deficient AML cells with empty vector or TSC2 addback (61) were transfected with siGENOME SMARTpool siRNAs (Dharmacon) targeting CCNT1, RNGTT, or CDK11, using Lipofectamine RNAiMAX transfection reagent (Invitrogen) according to the manufacturer's reverse transfection protocol. ATP concentrations were quantified using the CellTiter-Glo Luminescent Cell Viability Assay (Promega) according to the manufacturer's instructions. The following antibodies were purchased from Cell Signaling Technology and used for Western blot analysis: TSC2 (#3612), phospho-Thr 389 S6K (#9234), S6K (#2708), GAPDH (#5174), CCNT1 (#8744), and CDK11 (#5524). RNGTT antibody was purchased from Novus Biologicals (#NBP1-49972).
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